Thus, the impact of SNP309 on breast cancer risk appears to be limited to tumors in which p53 is functional, which is biologically plausible since the key function of MDM2 to negatively regulate p53 becomes irrelevant if p53 is inactivated by mutation. The gene discussed is TP53; the disease is breast carcinoma.